Novan’s Phase 2b Results with SB204 to be Presented at AAD

Abstract Accepted for Presentation by Dr. Lawrence Eichenfield During 2016 Late-breaking Research in Dermatology Forum

Novan, Inc. today announced that data from a Phase 2 clinical trial to evaluate the efficacy and safety of the Company’s topical nitric oxide product candidate SB204 Gel for the treatment of acne vulgaris will be presented at the 74th Annual Meeting of the American Academy of Dermatology (“AAD”) in Washington, D.C.